Health
New gene therapy could treat dominant optic atrophy – Drug Target Review
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Posted: 27 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Scientists have developed a new gene therapy approach that they say offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study was led by researchers at Trinity College Dublin, Ireland.
A fluorescent microscope…
-
Noosa News15 hours agoMitch Power Quick Shear event gets men talking about mental health
-
General17 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
Noosa News17 hours agoRaising your voice | Noosa Today
-
Noosa News8 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs